⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

July 3, 2024International Forum of Allergy & RhinologyOpen Access

Impact of elexacaftor/tezacaftor/ivacaftor CFTR modulator therapy on rates of endoscopic sinus surgery in cystic fibrosis

Graham Pingree Mihai A. Bentan Thomas H. Fitzpatrick Theodore A. Schuman

View Full Paper

Ask AI

Bookmark

Share

Abstract

Elexacaftor/tezacaftor/ivacaftor (ETI), a combination cystic fibrosis transmembrane receptor (CFTR) modulator, has demonstrated improved pulmonary outcomes in individuals with cystic fibrosis (CF). However, ETI's impact on functional endoscopic sinus surgery (FESS) remains unclear.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Pingree et al. (2024) studied this question.

synapsesocial.com/papers/68e61800b6db6435875aa426 https://doi.org/10.1002/alr.23400

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Elexacaftor–Tezacaftor–Ivacaftor Reduces Revision Sinus Surgery in People With Cystic Fibrosis2025
2Elexacaftor/Tezacaftor/Ivacaftor Improves Sinonasal Disease in Young Patients With Cystic Fibrosis: A Prospective Study2025 · 2 citations
3Impact of Elexacaftor–Tezacaftor–Ivacaftor Therapy on Body Composition, Dietary Intake, Biomarkers, and Quality of Life in People with Cystic Fibrosis: A Prospective Observational Study2024 · 23 citations
4Elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis and rare mutations2024 · 7 citations
5Longitudinal improvements in clinical and functional outcomes following initiation of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis2024 · 1 citations